A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies.

Trial Profile

A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2012

At a glance

  • Drugs Perifosine (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AEterna Zentaris Inc; AOI Pharmaceuticals; Keryx Biopharmaceuticals
  • Most Recent Events

    • 18 May 2012 Additional lead trial centre (AEterna Zentaris Inc) added as reported by ClinicalTrials.gov.
    • 01 May 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 30 Apr 2012 Planned end date changed from 1 Apr 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top